Ken Inoki

inokik's picture
University: 
University of Michigan - Ann Arbor
Unit: 
Life Sciences Institute
Department: 
Life Sciences Institute, Molecular and Integrative Physiology
Title: 
Research Associate Professor, Life Sciences Institute, Associate Professor of Molecular and Integrative Physiology and Internal Medicine, Medical School
Phone: 
734-763-1102
Short bio: 

 

Education:

B.S., M.D. Medicine, Shiga University of Medical Science, 1991

Ph.D. Biochemistry, Shiga University of Medical Science, 1998

 

Medical training:

Resident, The Third Department of Medicine, Department of Nephrology, Shiga University of Medical Science, 1991-1992

Resident, Osaka National Hospital, Department of Medicine, 1992-1994

Medical Instructor, The Division of Hemodialysis, Department of Nephrology, Shiga University of Medical Science, 1999-2001

 

Postdoctoral training:

Postdoctoral Research fellow, Mentor: Kun-liang Guan, Dept of Biochemistry,

University of Michigan, 2001-2004

Assistant Research Scientist, Life Sciences Institute, 2004-2008

Research summary: 

Ken Inoki is using biochemical and genetic approaches to examine how cells monitor cellular energy, nutrients, and growth factor signaling to regulate protein synthesis and cell growth, which has implications for diseases including cancer and diabetes.

Recent publications: 
  •   Narita M, Young A, Arakawa S, Samarajiwa SA, Nakashima T, Yoshida S, Hong S, Berry LS, Reichelt S, Ferreira M, Tavaré S, Inoki K, Shimizu S, Narita M. (2011) Spatial Coupling of mTOR and Autophagy Augments Secretory Phenotypes. Science. 332, 966-70.
  •   Gödel M, Hartleben B, Herbach N, Liu S, Zschiedrich S, Lu S, Debreczeni-Mór A, Lindenmeyer MT, Rastaldi MP, Hartleben G, Wiech T, Fornoni A, Nelson RG, Kretzler M, Wanke R, Pavenstädt H, Kerjaschki D, Cohen CD, Hall MN, Rüegg MA, Inoki K, Walz G, Huber TB. (2011) Role of mTOR for podocyte function and diabetic nephropathy progression in humans and mice. J Clin Invest. 121, 2197-209.
  •  Inoki K, Mori H, Wang J, Suzuki T, Hong S, Yoshida S, Blattner SM, Ikenoue T, Rüegg MA, Hall MN, Kwiatkowski DJ, Rastaldi MP, Huber TB, Kretzler M, Holzman LB, Wiggins RC, Guan KL. (2011) mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy. (*co-corresponding) J Clin Invest. 121, 2181-96.
  •   Yoshida S, Hong S, Suzuki T, Nada S, Mannan AM, Wang J, Okada M, Guan KL, Inoki K. (2011) Redox regulates mTORC1 activity by modulating the TSC1/TSC2-Rheb pathway. J Biol Chem 286, 326251-60.
  •   Kikuchi T, Zhang J, Sakoda H, Koketsu Y, Fujishiro M, Kushiyama A, Nakatsu Y, Kamata H, Inoki K, Takahashi S, Kurihara H, Hideki K, Oka Y, Asano T. (2012) LST8 level controls basal p70 S6 kinase and Akt phospohrylations, and mTORC1 and mTORC2 negatively regulate each other by competing for association with LST8. Obes Res Clin Pract, 6, e175-e262.
  •   Bridges D, Fisher K, Zolov SN, Xiong T, Inoki K, Weisman LS, Saltiel AR. (2012) Rab5 proteins regulate activation and localization of target of rapamycin complex 1. J Biol Chem. 287, 20913-21.
  •   Bridges D, Ma JT, Park S, Inoki K, Weisman LS, Saltiel AR. (2012) PI(3,5)P2 plays a role in the activation and subcellular localization of mTORC1. Mol Biol Cell. 23, 2955-2962.
  •   Bartholomew CR, Suzuki T, Du Z, Backues SK, Jin M, Lynch-Day MA, Umekawa M, Kamath A, Zhao M, Xie Z, Inoki K, Klionsky DJ. (2012) Ume6 transcription factor is part of a signaling cascade that regulates autophagy. Proc Natl Acad Sci U S A. 109, 11206-10.
  •   Fukuda A, Chowdhury MA, Venkatareddy MP, Wang SQ, Nishizono R, Suzuki T, Wickman LT, Wiggins JE, Muchayi T, Fingar D, Shedden KA, Inoki K, Wiggins RC. (2012) Growth-dependent podocyte failure causes glomerulosclerosis. J Am Soc Nephrol. 23, 1351-1363.
  •   Henry FE, McCartney AJ, Neely R, Perez AS, Carruthers CJ, Stuenkel EL, Inoki K, Sutton MA. (2012) Retrograde changes in presynaptic function driven by dendritic mTORC1. J Neurosci. 32, 17128-17142.
  •   Suzuki T, Bridges D, Nakada D, Skiniotis G, Morrison SJ, Lin J, Saltiel AR, Inoki K. (2013) Inhibition of AMPK catabolic action by GSK3. Mol Cell  50, 407-419.
  •   Tang H, Inoki K, Lee M, Wright E, Khuong A, Khuong A, Sugiarto S, Garner M, Paik J, Depinho RA, Goldman D, Guan KL, Shrager JB. (2014) mTORC1 promotes denervation-induced muscle atrophy trough a mechanism involving the activation of FoxO and E3 ubiquitin ligases. Sci Signal 7, 1-10.
  •   Hong S, Zhao B, Lombard DB, Fingar DC, Inoki K. (2014) Crosstalk between sirtuin and mammalian target of rapamycin complex 1 (mTORC1) signaling in the regulation of S6 kinase 1 (S6K1) phosphorylation. J Biol Chem 289, 13132-41.
  •   Zhang D, Tong X, Arthurs B, Guha A, Rui L, Kamath A, Inoki K, Yin L. (2014) Liver clock protein BMAL1 promotes de novo lipogenesis through insulin-mTORC2-AKT signaling. J Biol Chem 289, 25925-35.
  •   Park DW, Jiang S, Liu Y, Siegal GP, Inoki K, Abraham E, Zmijewski JW. (2014) GSK3β-dependent inhibition of AMPK potentiates activation of neutrophils and macrophages and enhances severity of acute lung injury. Am J Physiol Lung Cell Mol Physiol 307, L735-45.
  •   Yoshida S, Pacitto R, Yao Y, Inoki K, Swanson JA. (2015) Growth factor signaling to mTORC1 by amino acid-laden macropinosomes. J Cell Biol, Oct 5. pii: jcb.201504097.
Keywords: 
rapamycin,
mTOR,
S6K1,
AMPK,
Tuberous Sclerosis Complex,
cell growth control,
cancer development,
diabetic nephropathy
Delegates: 
maggieva